While it's been widely rumored for a while now that the iPad 5 would get the iPad mini's thinner, lighter design this year, rumors about the iPad mini getting the full-sized iPad's Retina display have been split down the middle - some "yes", some "no", some simply "hope so". Daisuke Wakabayashi and Ian Sherr, however, seem to think it's a done deal. From the Wall Street Journal:
Apple is now readying a revamped iPad Mini with a high-resolution "retina" display. It's also working on a thinner, lighter version of its standard 9.7-inch iPad, using a thin film instead of the glass found in existing models, based on information from the company's parts suppliers.
Given the power of the Apple A7 chipset, it's unlikely there'll be the same "Retina tax" paid by the iPad 3, which always felt like it was running on redline. That debt's been paid off. What remains a challenge for both a lighter iPad 5 and a Retina iPad 2 is battery life. Apple historically hasn't been willing to ship a tablet with under 10 hours of battery life, even going so far as to slightly increase the thickness and weight of the full-sized iPad when it went Retina in 2012.
Those 2048x1536 pixel screens require a lot of backlight and a lot of GPU power to push around. Since battery chemistry isn't getting much better, Apple has to rely on everything else, including advances in lighting, screen technology, and processor architecture.
If Apple has succeeded in getting both the iPad 5 slimmed down, and the iPad mini 2 Retina'd up, it'll be interesting to see what breakthroughs they've had, and what compromises they've had to make.
We'll find out on October 22. In the meantime, anyone starting to believe?
By the time champion cyclist Lance Armstrong confessed a career of doping to Oprah Winfrey in January, he'd already been stripped of his seven Tour de France titles and banned from further competition. Wall Street Journal reporters Reed Albergotti and Vanessa O'Connell covered and regularly broke stories about the investigation that ended Armstrong's career.
"It was amazing how quickly everything happened," Albergotti tells Fresh Air's Dave Davies. In "the second half of 2012, he went from being an athlete really on the top of the world, making a comeback in triathlon, to losing all of his sponsors, all of his income, all of his Tour de France titles. It just happened so fast and I think that hit him like a ton of bricks. He was completely shocked by that."
Albergotti and O'Connell have written a new book called Wheelmen which chronicles Armstrong's emergence as a rich and powerful athlete, and explores the remarkable breadth of the doping culture embraced by his pro cycling team. There were many co-conspirators, group blood transfusions on the team bus, and extensive efforts to silence and intimidate those who might expose the abuse.
Albergotti and O'Connell had several conversations with Armstrong in their reporting. Armstrong declined our invitation to appear on Fresh Air.
Interview Highlights
On how team racing works
RA: There are nine riders on each team in the Tour de France — and these are trade teams, they're not national teams so the riders can be from all over the world. In Lance Armstrong's case they were the United States Postal Service Team, and eight of those nine riders will all take turns essentially blocking the wind in order to make it as easy as possible for that ninth rider, Lance Armstrong, to ultimately finish as high as possible in the overall standings in the race. Now, the Tour de France is three weeks long, so every bit of energy savings makes a huge difference over the course of those three weeks, so on the Postal Service Team the stronger Lance's eight teammates were, the better off he was because they could stay in the wind where they have to pedal 30 percent harder, blocking the wind for Lance.
... The name for those guys is "domestique," ... to be a domestique in the Tour de France, it's like being a starter in the Super Bowl. You might not be the quarterback, but you're playing a very important role. It means you're really one of the top 200 cyclists on the planet.
As entrepreneurship editor for The Wall Street Journal, Vanessa O'Connell created The Accelerators, a blog on startup companies.
The Wall Street Journal
As entrepreneurship editor for The Wall Street Journal, Vanessa O'Connell created The Accelerators, a blog on startup companies.
The Wall Street Journal
On an admission Armstrong made while he was undergoing cancer treatment
VO'C: [Armstrong] was in the hospital on a Saturday when, according to Betsy Andreu, who is the wife of one of his teammates, Frankie Andreu was there as well. The doctor came in and asked him if he had ever done performance enhancing drugs and he answered, "Yes," and listed human growth hormone, testosterone and other performance enhancing drugs that he had done. So that was a very important scene in the book and in Armstrong's story, because later when there were allegations that he had used performance enhancing drugs, Armstrong denied that that had ever happened. There was an arbitration, way back in 2005, 2006, where there was a lot of testimony taken, it was a confidential arbitration, and that hospital room scene was pivotal. The arbitration ended without ever having any kind of finding of whether Armstrong had ever used performance enhancing drugs, but during the arbitration there was a lot of pretty damning testimony about that hospital room scene and about what Armstrong had said.
Reed Albergotti was a founding reporter in the sports department of The Wall Street Journal, where he has worked since 2003.
Michael Nathaniel Meyer/Dow Jones
Reed Albergotti was a founding reporter in the sports department of The Wall Street Journal, where he has worked since 2003.
Michael Nathaniel Meyer/Dow Jones
On the new method of blood doping
RA: Eventually there was a test for EPO [a popular performance enhancing drug], it was detectable in urine tests, so they had to find new ways to boost their red blood cell count. What they settled on was blood transfusions and that involved taking out about a half liter of blood, months, weeks before the Tour de France, and then re-infusing that blood during the race. And essentially what they were doing was increasing the amount of blood in their body beyond what its normal capacity was, so they had more red blood cells, more oxygen going to their muscles, it was essentially the same thing as taking EPO, but it was their own blood so it was very difficult to test for. Once they started doing that it became much more complicated because you had all these people watching over you, the French law enforcement were raiding hotel rooms during the Tour, and to get away with doing two blood transfusions per rider per race, which is what they ultimately did, it involved transporting blood in motorcycles with refrigerated saddle bags and unmarked trailers and campers and multiple doctors, so it was a huge operation in the end.
“ One night, as their team bus was driving back to their hotel room, the bus pulls over on the side of the road, the bus driver gets out and puts up some cones as if the bus is broken down, but it hadn't broken down, actually. They wanted to do a secret blood transfusion on the side of the road and the broken down bus was the decoy.
- Reed Albergotti
On the shocking discovery of how the team did a secret blood transfusion
RA: During the 2004 Tour de France they were extremely worried about French law enforcement so they had already done one re-infusion of blood on the first rest day during that race ... and they wanted to do another one. None of the riders really knew exactly when this was going to take place, but one night, as their team bus was driving back to their hotel room, the bus pulls over on the side of the road, the bus driver gets out and puts up some cones as if the bus is broken down, but it hadn't broken down, actually. They wanted to do a secret blood transfusion on the side of the road and the broken down bus was the decoy. So all of the riders lie down on the floor of the bus, team doctors hang blood bags from the luggage racks, and connect the end of those bags to the riders' veins.
On Armstrong's ability to cover his tracks
RA: There really was a scandal every single year and because of his position as this crusader against cancer he was larger than life and people did not want to believe that he could cheat in bike racing. So they really just — and this includes mainstream media — ignored all of this evidence that showed that he was doping. He was so charismatic and able to lie to the face of so many people including all of his followers and convince them that all of these allegations were completely false.
VO'C: In hindsight Armstrong had two very powerful arguments that really held sway with the public: One was, "I survived cancer, why would I take drugs? Why would I do that to myself?" That was an argument that I think really resonated with the public even though it was as lie. The other is, "I've been tested hundreds of times and I've never had a positive drug test." And people really also bought into that. They didn't fully understand that it was easy for the cyclists to beat these tests and get around them, and that drug testing at that time was meaningless.
On what could be next for Armstrong
RA: I think a lot of it depends on the outcome of the whistleblower lawsuit. If he loses a significant chunk of his net worth then he's going to have find some way to make income and he can't compete, at least not now, so I think there are so many questions.
VO'C: Although we can't pretend to know what Armstrong will do, I think that it's likely that he'll try to come out with his own narrative, his own account, if he can, when the time is right. I don't think that time will be anytime particularly soon, but I'm sure he feels that he has a story to tell and he would like to get his side fully out so we can anticipate he'll make an attempt to do that, and certainly, he'll make an attempt to rehabilitate his image, when he feels the coast is clear and the time is right. How far that will go, or how successful that will be will really depend on how he does that and whether people believe that he is truly remorseful.
While it's been widely rumored for a while now that the iPad 5 would get the iPad mini's thinner, lighter design this year, rumors about the iPad mini getting the full-sized iPad's Retina display have been split down the middle - some "yes", some "no", some simply "hope so". Daisuke Wakabayashi and Ian Sherr, however, seem to think it's a done deal. From the Wall Street Journal:
Apple is now readying a revamped iPad Mini with a high-resolution "retina" display. It's also working on a thinner, lighter version of its standard 9.7-inch iPad, using a thin film instead of the glass found in existing models, based on information from the company's parts suppliers.
Given the power of the Apple A7 chipset, it's unlikely there'll be the same "Retina tax" paid by the iPad 3, which always felt like it was running on redline. That debt's been paid off. What remains a challenge for both a lighter iPad 5 and a Retina iPad 2 is battery life. Apple historically hasn't been willing to ship a tablet with under 10 hours of battery life, even going so far as to slightly increase the thickness and weight of the full-sized iPad when it went Retina in 2012.
Those 2048x1536 pixel screens require a lot of backlight and a lot of GPU power to push around. Since battery chemistry isn't getting much better, Apple has to rely on everything else, including advances in lighting, screen technology, and processor architecture.
If Apple has succeeded in getting both the iPad 5 slimmed down, and the iPad mini 2 Retina'd up, it'll be interesting to see what breakthroughs they've had, and what compromises they've had to make.
We'll find out on October 22. In the meantime, anyone starting to believe?
New iPads! That’s the suspected plan for tomorrow’s Apple event. With much of the consumer attention now turning to the more discreet form factor of the iPad Mini, Apple’s iPad 5 needs to justify its full-size existence. And that justification may now come in the form of an Apple-built, pro-orientated keyboard cover.
Lifetime is reviving Betty White's Off Their Rockers.
The female-skewing cable network has picked up 20 original half-hour episodes of the hidden-camera series, The Hollywood Reporter has learned exclusively.
White will return to host the third season of the series in 2014. A formal premiere date has not yet been determined.
The deal with producer Kinetic Content brings new episodes of the series to Lifetime, which has aired off-network repeats.
NBC aired the first two seasons of the series, which featured White overseeing the elderly playing pranks on younger folks in a hidden-camera fashion similar to Candid Camera. The show launched with a preview in April 2012 timed to an NBC special tribute for White's 90th birthday earning 12 million total viewers.
Following its 12-episode run from January to May 2012, NBC renewed the series for a second run of 14 installments, which started with back-to-back airings in January into February with its final four episodes airing March 19, June 25 and July 9.
Rockers' most recent in-season run -- which was used to help fill holes on the network and often held up well -- averaged a 1.5 rating with adults 18-49 and 5.3 million viewers. The series failed to really see an uptick when factoring in Live+Seven-Day numbers as the show didn't traditionally perform well with the DVR crowd.
Rockers marks the latest series to be spared the ax at Lifetime. The cable network revived America's Most Wanted for a 25th season after Fox dropped the John Walsh crime-fighting series after 24 runs. (Lifetime ultimately canceled the series in March.) The network also picked up ABC's DeviousMaidsafter the network originally passed on the Marc Cherry drama. That series has already been renewed for a second season.
New Jersey Inventors Hall of Fame to honor NJIT researchers and alumnus tonight at annual awards banquet
Public release date: 17-Oct-2013 [
| E-mail
| Share
]
Contact: Tanya Klein 973-596-3433 New Jersey Institute of Technology
Three members of the New Jersey Institute of Technology (NJIT) community will be honored this evening by the New Jersey Inventors Hall of Fame (NJIHoF) in recognition of their contributions to innovation in the Garden State. Treena Livingston Arinzeh, PhD, Roberto Rojas-Cessa, PhD, and Khondaker M. Salehin, PhD, will receive awards at a formal banquet on Oct. 17, 2013 at the W Hotel in Hoboken.
Treena Livingston Arinzeh and Roberto Rojas-Cessa will each accept an Innovators Award, which recognizes significant scientific achievement. Dr. Arinzeh, a professor of biomedical engineering, will be recognized for her renowned research and inventions utilizing biomaterials and regenerative medicines for orthopedic and neural disorders. Earlier this month, Arinzeh was awarded the NJIT Board of Overseers Excellence in Research Prize and Medal in recognition of a sustained record of contributions that has enhanced the reputation of NJIT. Dr. Rojas-Cessa, an associate professor in the Department of Electrical and Computer Engineering, will be honored for his renowned research in the areas of broadband and high-speed networks and a wide range of computer communication technology applications.
Accepting a Graduate Student Award will be Khondaker M. Salehin, PhD, an adjunct professor in the Department of Electrical and Computer Engineering, in recognition of his patents related to advancing schemes for measurements of Internet performance parameters. Dr. Salehin, who received his doctoral degree from NJIT in May 2013, collaborates with Dr. Rojas-Cessa on his research.
Established in 1987, The New Jersey Inventors Hall of Fame promotes and fosters creativity, invention and innovation, which contributes to economic growth and improvement of the quality of life in New Jersey and around the globe. The organization, unique to the State of New Jersey, honors inventors, innovators, and others who have created and developed their inventions in the State of New Jersey, "The Invention State".
###
NJIT, New Jersey's science and technology university, enrolls approximately 10,000 students pursuing bachelor's, master's and doctoral degrees in 127 programs. The university consists of six colleges: Newark College of Engineering, College of Architecture and Design, College of Science and Liberal Arts, School of Management, College of Computing Sciences and Albert Dorman Honors College. U.S. News & World Report's 2014 Annual Guide to America's Best Colleges ranked NJIT in the top tier of national research universities. NJIT is internationally recognized for being at the edge in knowledge in architecture, applied mathematics, wireless communications and networking, solar physics, advanced engineered particulate materials, nanotechnology, neural engineering and e-learning. Many courses and certificate programs, as well as graduate degrees, are available online through the Division of Continuing Professional Education.
[
| E-mail
| Share
]
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
New Jersey Inventors Hall of Fame to honor NJIT researchers and alumnus tonight at annual awards banquet
Public release date: 17-Oct-2013 [
| E-mail
| Share
]
Contact: Tanya Klein 973-596-3433 New Jersey Institute of Technology
Three members of the New Jersey Institute of Technology (NJIT) community will be honored this evening by the New Jersey Inventors Hall of Fame (NJIHoF) in recognition of their contributions to innovation in the Garden State. Treena Livingston Arinzeh, PhD, Roberto Rojas-Cessa, PhD, and Khondaker M. Salehin, PhD, will receive awards at a formal banquet on Oct. 17, 2013 at the W Hotel in Hoboken.
Treena Livingston Arinzeh and Roberto Rojas-Cessa will each accept an Innovators Award, which recognizes significant scientific achievement. Dr. Arinzeh, a professor of biomedical engineering, will be recognized for her renowned research and inventions utilizing biomaterials and regenerative medicines for orthopedic and neural disorders. Earlier this month, Arinzeh was awarded the NJIT Board of Overseers Excellence in Research Prize and Medal in recognition of a sustained record of contributions that has enhanced the reputation of NJIT. Dr. Rojas-Cessa, an associate professor in the Department of Electrical and Computer Engineering, will be honored for his renowned research in the areas of broadband and high-speed networks and a wide range of computer communication technology applications.
Accepting a Graduate Student Award will be Khondaker M. Salehin, PhD, an adjunct professor in the Department of Electrical and Computer Engineering, in recognition of his patents related to advancing schemes for measurements of Internet performance parameters. Dr. Salehin, who received his doctoral degree from NJIT in May 2013, collaborates with Dr. Rojas-Cessa on his research.
Established in 1987, The New Jersey Inventors Hall of Fame promotes and fosters creativity, invention and innovation, which contributes to economic growth and improvement of the quality of life in New Jersey and around the globe. The organization, unique to the State of New Jersey, honors inventors, innovators, and others who have created and developed their inventions in the State of New Jersey, "The Invention State".
###
NJIT, New Jersey's science and technology university, enrolls approximately 10,000 students pursuing bachelor's, master's and doctoral degrees in 127 programs. The university consists of six colleges: Newark College of Engineering, College of Architecture and Design, College of Science and Liberal Arts, School of Management, College of Computing Sciences and Albert Dorman Honors College. U.S. News & World Report's 2014 Annual Guide to America's Best Colleges ranked NJIT in the top tier of national research universities. NJIT is internationally recognized for being at the edge in knowledge in architecture, applied mathematics, wireless communications and networking, solar physics, advanced engineered particulate materials, nanotechnology, neural engineering and e-learning. Many courses and certificate programs, as well as graduate degrees, are available online through the Division of Continuing Professional Education.
[
| E-mail
| Share
]
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Source: http://feedproxy.google.com/~r/TheIphoneBlog/~3/F-GK-SLhc3U/story01.htm
Source: ![[ Back to EurekAlert! ]](https://lh3.googleusercontent.com/blogger_img_proxy/AEn0k_t9895CbwaF_LA8y8wZRNSTuUBmoziPfM4SmvAXWHZr5wM5Q37u2XFDUZ6UXeOrSoYj_Qmw4qnJGKppu9oZ0hQG0Ix23WLOQOHyewDJVw8=s0-d){kind=small}
Share